aibioVSBC VITASPRING BIOMEDICAL CO. LTD.
VITASPRING BIOMEDICAL CO. LTD. (VSBC) news
VITASPRING BIOMEDICAL CO. LTD. is a public biotech or pharmaceutical company listed on OTC under the ticker VSBC, recorded under United States. aibio.space tracks 2,820 public biotech companies worldwide and publishes investor news on them.
Latest VITASPRING BIOMEDICAL CO. LTD. news
We have not published a story on VITASPRING BIOMEDICAL CO. LTD. yet. When there is news, it will appear here.
What VITASPRING BIOMEDICAL CO. LTD. does
VitaSpring Biomedical Co. Ltd., formerly Shemn Corp., describes itself as a development-stage biomedical company engaged in research, development and commercialization of wellness products. Its research centres on a mesenchymal stem cell it calls X.msc, which the filing says is derived from non-embryonic human placental tissue, and on exosome-based materials derived from those cells. The company's stated focus areas are regenerative medicine, preventive health care, beauty and anti-aging. The filing says it does not sell any products or treatments for consumer use, and that its scientific descriptions are based on historical research and on information from affiliated collaborators. It has not submitted any applications to the FDA, initiated any clinical programs, or received authorization to market any regulated biomedical product. It also says it did not conduct research and development activities during the fiscal years ended January 31, 2026 and 2025, and that future work depends on financing. Its management has described plans for a stem cell bank designed to operate in compliance with FDA regulations, and it works with affiliated research collaborators in Taiwan and other parts of Asia-Pacific.
| Product or program | What it is | Stage |
|---|---|---|
| X.msc mesenchymal stem cell platform | Placenta-derived stem cell platform for regenerative medicine research | early development stage; not yet completed scientific testing |
| Exosome-based formulations | Exosome materials under study for skin care, wound healing and anti-inflammatory research | prototype formulations under consideration |
VITASPRING BIOMEDICAL CO. LTD. annual financials
Questions about VITASPRING BIOMEDICAL CO. LTD.
What is the ticker symbol of VITASPRING BIOMEDICAL CO. LTD.?
VITASPRING BIOMEDICAL CO. LTD. trades under the ticker VSBC on OTC.
Where is VITASPRING BIOMEDICAL CO. LTD. listed?
VITASPRING BIOMEDICAL CO. LTD. is listed on OTC.
Which country or territory is VITASPRING BIOMEDICAL CO. LTD. listed under?
Our directory records VITASPRING BIOMEDICAL CO. LTD. under United States.
Does aibio.space cover VITASPRING BIOMEDICAL CO. LTD.?
aibio.space lists VITASPRING BIOMEDICAL CO. LTD. among 2,820 public biotech companies and publishes its news here as stories appear.
What does VITASPRING BIOMEDICAL CO. LTD. develop?
VitaSpring Biomedical Co. Ltd., formerly Shemn Corp., describes itself as a development-stage biomedical company engaged in research, development and commercialization of wellness products. Its research centres on a mesenchymal stem cell it calls X.msc, which the filing says is derived from non-embryonic human placental tissue, and on exosome-based materials derived from those cells.
What is X.msc mesenchymal stem cell platform from VITASPRING BIOMEDICAL CO. LTD.?
X.msc mesenchymal stem cell platform: Placenta-derived stem cell platform for regenerative medicine research Stage: early development stage; not yet completed scientific testing.
What is Exosome-based formulations from VITASPRING BIOMEDICAL CO. LTD.?
Exosome-based formulations: Exosome materials under study for skin care, wound healing and anti-inflammatory research Stage: prototype formulations under consideration.
What was VITASPRING BIOMEDICAL CO. LTD.'s revenue last year?
$0 for the fiscal year ended Jan 31, 2026, as reported to the SEC.
Is VITASPRING BIOMEDICAL CO. LTD. profitable?
VITASPRING BIOMEDICAL CO. LTD. reported a net loss of $415,368 for the fiscal year ended Jan 31, 2026, and used $2,688 of cash in operations, per its annual report to the SEC.
How much cash does VITASPRING BIOMEDICAL CO. LTD. have?
$13,367 in cash at Jul 31, 2026, per its 10-Q.
Investor discussion: VITASPRING BIOMEDICAL CO. LTD.
Rules
- Securities violations are strictly forbidden. No market manipulation, no pump-and-dump, no false or misleading statements, and no inside information.
- Say whether you hold the stock. Every post states long, short or no position.
- No paid or sponsored posts. Do not post for anyone who pays or rewards you.
- No buy or sell calls and no price targets.
- No accusations of crime or fraud against named people unless you link a court filing or a regulator's release that makes them.
- No personal details and no spam. No links at all for your first 7 days as a member.
Capital-markets timeline
- Distress
Told the SEC a periodic report would be filed late. SEC Form NT 10-Q. Source
Stock chart
Listing details
- Company
- VITASPRING BIOMEDICAL CO. LTD.
- Ticker
- VSBC
- Listing
- OTC
- Country or territory
- United States
Who manages this page This page is managed by aibio.space. The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. How we work · Terms · Request a correction